Most of the new crown vaccines currently available need to be refrigerated and the manufacturing process is complex, which makes it difficult for them to be widely produced and distributed, especially in less developed countries. According to a recent report by physicist organization network, researchers at Boston Children's Hospital in the United States published a paper in the latest issue of the proceedings of the National Academy of Sciences, saying that they have designed a new vaccine, which is expected to change this situation. This vaccine is not only easier to produce, but also does not need to be stored in cold storage. The researchers point out that the vaccine produced a strong immune response to COVID-19 and its mutant strains in mice. It can be successfully lyophilized and then restored without loss of efficacy. In the experiment, the vaccine was stably and effectively stored at room temperature for at least 7 days. Their latest technology not only helps to fill the gap in global vaccination, but also can be used to develop vaccines against other diseases. Unlike the current new crown vaccine, the new vaccine is made entirely of protein: two components from the alpaca antibody - nanoscale and the spike protein part of COVID-19 combined with human cell receptors. Nanoparticles are a key component of this vaccine. They are designed to target key cells in the immune system - antigen-presenting cells, which enables spike protein fragments to enter cells directly and "display" them to other immune cells to induce a broader immune response. In the mouse experiment, the vaccine stimulated strong humoral immunity against COVID-19, stimulated a large number of neutralizing antibodies targeting the spike protein fragments, and induced strong cellular immunity, stimulated the production of helper T cells, and assembled other immune defense systems. The first author of the study and Novaliya Paisisha pointed out: "in addition, we can link the whole spike protein or other parts of the virus, and quickly and easily modify the vaccine to deal with the variant strain of COVID-19." Because the new vaccine is a protein rather than messenger RNA like Pfizer and Modena vaccines, it is more suitable for mass production. "We don't need a lot of technology and expertise to make mRNA vaccines. Biopharmaceutical companies have rich experience in large-scale production of protein based therapies, which enables new vaccines to be produced in many locations and used in situ," the researchers explained The research team has applied for a patent for the new technology and hopes to cooperate with biotechnology or pharmaceutical companies to carry out further tests and finally carry out clinical trials. (outlook new era)